10 December 2018 - - US-based biotechnology company Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) presented data from the Phase 3 RECOVER clinical study during the 2018 San Antonio Breast Cancer Symposium(SABCS) recently, the company said.

These data confirm the efficacy and safety of Rolontis (eflapegrastim) in reducing the Duration of Severe Neutropenia in breast cancer patients treated with chemotherapy.

Rolontis is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) being studied as a treatment for neutropenia in patients undergoing treatment with myelosuppressive cytotoxic chemotherapy.

The data released yesterday in a poster presentation from the ROLONTIS Phase 3 RECOVER study (n=237) showed that in Cycle 1, the mean DSN±SD was 0.31±0.688 days for Rolontis and 0.39±0.949 days for pegfilgrastim, demonstrating non-inferiority (p